WeTrials
Active, not recruiting

A Phase 2, Open-Label, Randomized Trial Evaluating the Impact of Enhanced Versus Standard Dermatologic Management on Selected Dermatologic Adverse Events Among Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC Treated First-Line With Amivantamab + Lazertinib

What is this study?

This study is testing ways to better manage and prevent skin-related side effects in lung cancer patients receiving targeted cancer therapies. The goal is to see if proactive skin care can reduce rashes and other skin discomforts compared to standard care.

Who can participate?

You may be eligible if you have advanced non-small cell lung cancer with a specific EGFR genetic mutation and have not yet received whole-body treatment for your advanced cancer. Participants also need to meet general health and safety guidelines.

What will happen?

Participants will receive cancer treatments along with specialized skin management plans, which may include lotions, antibiotics, creams, or washes to prevent and treat skin side effects. Your care team will closely monitor your skin health and overall well-being throughout the study.

Where and when?

This study has locations in Arizona and California, and it is currently active but not recruiting new participants.

Key Points
  • 1Focuses on preventing and treating skin side effects from lung cancer therapy
  • 2Compares enhanced skin management to standard care approaches
  • 3Currently active but not open to new participants

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Carcinoma, Non-Small-Cell Lung

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.